Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.38 |
| ▸ | PTN | P21246 | 2/20 | 0.38 |
| ▸ | MDK | P21741 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689074 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL30089326 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL22362645 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL15966272 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL15965653 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL23631128 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL15966248 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL20474503 | 0.88 | MAPK1 (0.45) | BDNFPTNMDKALDH1A1THRB | |
| SCHEMBL16566075 | 0.84 | ALDH1A1 (0.40) | BDNFPTNMDKALDH1A1THRB | |
| Phosphoric Acid SCHEMBL27756060 | 0.83 | AMDHD2 (0.46) | BDNFPTNMDKALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-10788499-B2 | Methods for assaying palmitoyl protein thioesterase 1 and tripeptidyl peptidase activity in dried blood spots for detection of neuronal ceroid lipofuscinoses in newborns | UNIVERSITY OF WASHINGTON (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190144916-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-05-16 | — | — | US | disclosed |
| US-10196668-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180209989-A1 | METHODS FOR ASSAYING PALMITOYL PROTEIN THIOESTERASE 1 AND TRIPEPTIDYL PEPTIDASE ACTIVITY IN DRIED BLOOD SPOTS FOR DETECTION OF NEURONAL CEROID LIPOFUSCINOSES IN NEWBORNS | UNIVERSITY OF WASHINGTON (US) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144916-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | GAA, MAN2B1, CLN6 | BDNF 4504/4885PTN 1621/4885MDK 2814/4885 |
| US-10196668-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | GAA, GBA1, MAN2B1 | BDNF 2656/4885PTN 1714/4885MDK 1711/4885 |
| US-20180209989-A1 | METHODS FOR ASSAYING PALMITOYL PROTEIN THIOESTERASE 1 AND TRIPEPTIDYL PEPTIDASE ACTIVITY IN DRIED BLOOD SPOTS FOR DETECTION OF NEURONAL CEROID LIPOFUSCINOSES IN NEWBORNS | PPT1, TPP1, SPTLC1 | BDNF 1803/4885PTN 1527/4885MDK 3002/4885 |
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | GAA, MAN2B1, CLN6 | BDNF 4504/4885PTN 1621/4885MDK 2814/4885 |
| US-10788499-B2 | Methods for assaying palmitoyl protein thioesterase 1 and tripeptidyl peptidase activity in dried blood spots for detection of neuronal ceroid lipofuscinoses in newborns | PPT1, TPP1, SPTLC1 | BDNF 1803/4885PTN 1527/4885MDK 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.